Comparison of characteristics of individuals in each recommendation category (based on primary recommendation)
| In control N=14 989 | Not well controlled N=1245 | ||||||
|---|---|---|---|---|---|---|---|
| Maintain n=9564 | Maintain/decrease n=4349 | Decrease n=474 | Duplicate/inappropriate n=602 | Increase n=1090 | Refer n=17 | Duplicate/inappropriate n=138 | |
| Age mean (SD) | 41.8 (19.2) | 38.2 (22.7) | 44.8 (21.6) | 45.9 (20.3) | 40.4 (21.5) | 57.1 (9.3) | 46.6 (16.0) |
| Age n (%) | |||||||
| ≤17 | 919 (9.6) | 1115 (25.6) | 74 (15.6) | 68 (11.3) | 189 (17.3) | 0 | 6 (4.4) |
| 18–39 | 3561 (37.2) | 996 (22.9) | 86 (18.1) | 123 (20.4) | 310 (28.4) | 0 | 33 (23.9) |
| 40–59 | 2987 (31.2) | 1269 (29.2) | 195 (41.1) | 260 (43.2) | 372 (34.1) | 10 (58.8) | 79 (57.2) |
| ≥60 | 2097 (21.9) | 969 (22.3) | 119 (25.1) | 151 (25.1) | 219 (20.1) | 7 (41.2) | 20 (14.5) |
| Sex n (% female) | 6073 (63.5) | 2659 (61.1) | 303 (63.9) | 381 (63.3) | 709 (65.0) | 12 (70.6) | 101 (73.2) |
| Income n (%) * | |||||||
| Low SES | 1684 (17.6) | 923 (21.2) | 117 (24.7) | 156 (25.9) | 237 (21.7) | 4 (23.5) | 43 (31.2) |
| Middle SES | 7028 (73.5) | 3161 (72.7) | 330 (69.6) | 420 (69.8) | 802 (73.6) | 13 (76.5) | 90 (65.2) |
| High SES | 763 (8.0) | 228 (5.2) | 25 (5.3) | 22 (3.6) | 47 (4.3) | 0 | 5 (3.6) |
| Medical visits mean (SD) past year | |||||||
| All | 8.78 (13.1) | 9.68 (13.8) | 12.62 (13.3) | 12.87 (13.4) | 16.52 (22.2) | 29.29 (21.3) | 24.99 (26.1) |
| Ambulatory | 7.72 (9.6) | 8.31 (9.2) | 10.89 (9.5) | 11.13 (9.5) | 13.53 (15.0) | 19.94 (10.0) | 20.01 (18.1) |
| Hospitalised | 1.07 (6.8) | 1.37 (7.7) | 1.73 (7.4) | 1.73 (7.6) | 2.99 (11.6) | 9.35 (16.4) | 4.98 (13.3) |
| Medical visits n (%) past year | |||||||
| Physician | |||||||
| 0 | 1036 (10.8) | 265 (6.1) | 14 (3.0) | 22 (3.6) | 62 (5.7) | 0 | 7 (5.1) |
| 1 | 1048 (10.96) | 451 (10.4) | 31 (6.5) | 40 (6.6) | 76 (7.0) | 0 | 5 (3.6) |
| 2 | 1000 (10.5) | 486 (11.2) | 41 (8.6) | 26 (4.3) | 81 (7.4) | 0 | 2 (1.4) |
| 3 or more | 6480 (67.8) | 3147 (72.4) | 388 (81.9) | 514 (85.4) | 871 (79.9) | 17 (100) | 124 (89.9) |
| ER visits | |||||||
| 0 | 5995 (62.7) | 2501 (57.5) | 240 (50.6) | 289 (48.0) | 200 (18.4) | 1 (5.9) | 25 (18.1) |
| 1 | 1565 (16.4) | 790 (18.2) | 89 (18.8) | 118 (19.6) | 221 (20.3) | 3 (17.6) | 21 (15.2) |
| 2 | 846 (8.8) | 414 (9.5) | 59 (12.4) | 63 (10.5) | 172 (15.8) | 1 (5.9) | 9 (6.5) |
| 3 or more | 1158 (12.1) | 644 (14.8) | 86 (18.1) | 132 (21.9) | 497 (45.6) | 12 (70.6) | 83 (60.2) |
| ED visits for respiratory problems | |||||||
| 0 | 8781 (91.8) | 3792 (87.2) | 394 (83.1) | 491 (81.6) | 294 (27.0) | 4 (23.5) | 38 (27.5) |
| 1 | 593 (6.2) | 402 (9.2) | 52 (11.0) | 64 (10.6) | 450 (41.3) | 4 (23.5) | 27 (19.6) |
| 2 | 142 (1.5) | 105 (2.4) | 15 (3.2) | 25 (4.2) | 188 (17.2) | 3 (17.65) | 22 (15.9) |
| 3 or more | 48 (0.5) | 50 (1.2) | 13 (2.7) | 22 (3.7) | 158 (14.5) | 6 (35.3) | 51 (37.0) |
| ED visits NOT for respiratory problems | |||||||
| 0 | 6268 (65.5) | 2712 (62.4) | 265 (55.9) | 326 (54.2) | 456 (41.8) | 4 (23.5) | 45 (32.6) |
| 1 | 1535 (16.1) | 742 (17.1) | 94 (19.8) | 118 (19.6) | 205 (18.8) | 3 (17.6) | 29 (21.0) |
| 2 | 746 (7.8) | 370 (8.5) | 49 (10.3) | 58 (9.6) | 117 (10.7) | 3 (17.6) | 14 (10.1) |
| 3 or more | 1015 (10.6) | 525 (12.1) | 66 (13.9) | 100 (16.6) | 312 (28.6) | 7 (41.2) | 50 (36.2) |
| Hospitalisation (days) | |||||||
| 0 | 8046 (84.1) | 3581 (82.3) | 356 (75.1) | 449 (74.6) | 774 (71.0) | 5 (29.4) | 78 (56.5) |
| 1 | 697 (7.3) | 318 (7.3) | 39 (8.2) | 62 (10.3) | 100 (9.2) | 3 (17.6) | 17 (12.3) |
| 2 | 215 (2.2) | 107 (2.5) | 20 (4.2) | 23 (3.8) | 44 (4.0) | 1 (5.9) | 3 (2.2) |
| 3 or more | 606 (6.3) | 343 (7.9) | 59 (12.4) | 68 (11.3) | 172 (15.8) | 8 (47.1) | 40 (29.0) |
| Hospitalisation for respiratory problems (days) | |||||||
| 0 | 9370 (98.0) | 4210 (96.8) | 447 (94.3) | 563 (93.5) | 990 (90.8) | 14 (82.4) | 109 (79.0) |
| 1 | 100 (1.0) | 60 (1.4) | 7 (1.5) | 20 (3.3) | 33 (3.0) | 0 | 7 (5.1) |
| 2 | 32 (0.3) | 32 (0.74) | 4 (0.8) | 5 (0.8) | 14 (1.3) | 0 | 3 (2.2) |
| 3 or more | 62 (0.6) | 47 (1.1) | 16 (3.4) | 14 (2.3) | 53 (4.9) | 3 (17.6) | 19 (13.8) |
| Asthma medications mean (SD) range past year | |||||||
| FABA | 0.61 (1.7) | 2.93 (3.8) | 4.32 (5.2) | 4.95 (5.1) | 2.50 (4.4) | 5.00 (5.2) | 6.82 (6.8) |
| ICS | 0.2 (0.7) | 2.3 (2.9) | 1.4 (2.6) | 3.6 (3.8) | 1.4 (2.4) | 0.9 (1.7) | 3.5 (3.9) |
| Leukotrienes | 0.1 (1.4) | 0.4 (3.0) | 6.7 (10.0) | 1.5 (4.8) | 0.8 (4.4) | 3.3 (5.1) | 3.9 (11.5) |
| Combination therapy | 0.0 (0.4) | 1.2 (2.9) | 5.1 (4.9) | 2.18 (3.9) | 1.0 (2.7) | 7.7 (4.5) | 3.0 (4.3) |
| Other | 0.2 (1.8) | 0.8 (3.4) | 2.9 (6.8) | 2.36 (3.9) | 1.8 (17.0) | 2.1 (2.5) | 4.45 (6.6) |
| Control status n (%) | |||||||
| Overuse FABA | 0 | 0 | 0 | 0 | 1 (0.1) | 0 | 0 |
| ER visits for Asthma | 0 | 0 | 0 | 0 | 1076 (98.7) | 17 (100) | 135 (97.8) |
| ER or FABA | 0 | 0 | 0 | 0 | 1076 (98.7) | 17 (100) | 135 (97.8) |
| Comorbidity Index | 1.6 (1.5) | 1.6 (1.5) | 1.8 (1.6) | 1.9 (1.9) | 1.8 (2.0) | 2.2 (1.4) | 2.6 (2.5) |
Less than 1% of missing values for each category.
ED, emergency department; FABA, fast-acting β agonist; SES, socioeconomic status.